3-((2,2,2-trifluoroethyl)amino)propan-1-ol | 767629-92-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-((2,2,2-trifluoroethyl)amino)propan-1-ol
• 英文别名: 3-[(2,2,2-Trifluoroethyl)amino]propan-1-ol；3-(2,2,2-trifluoroethylamino)propan-1-ol
• CAS: 767629-92-5
• 化学式: C₅H₁₀F₃NO
• mdl: MFCD12179429
• 分子量: 157.136
• InChiKey: ABNOVCYQWFZTPI-UHFFFAOYSA-N

物化性质

• 沸点：
  153.6±40.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-(cyclopropanecarboxamido)imidazo[1,2-a]pyridin-6-yl)thiophene-2-carboxylic acid 、 3-((2,2,2-trifluoroethyl)amino)propan-1-ol 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以23%的产率得到4-(2-(cyclopropanecarboxamido)imidazo[1,2-a]pyridin-6-yl)-N-(3-hydroxypropyl)-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide
  参考文献：
  名称：

  [EN] HETEROARYLAMIDE INHIBITORS OF TBK1
  [FR] INHIBITEURS HÉTÉROARYLAMIDE DE TBK1

  摘要：

  本发明提供了化合物的公式1：这些化合物可用作TBK-1的抑制剂，以及与之相关的药物组合物、治疗与TBK1相关疾病的方法、制备这些化合物及其中间体的工艺。

  公开号：

  WO2015134171A1

文献信息

• Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies
  作者：Kevin Lou、Yuemang Yao、Adam T. Hoye、Michael J. James、Anne-Sophie Cornec、Edward Hyde、Bryant Gay、Virginia M.-Y. Lee、John Q. Trojanowski、Amos B. Smith、Kurt R. Brunden、Carlo Ballatore

  DOI：10.1021/jm5005623

  日期：2014.7.24

  Microtubule (MT) stabilizing drugs hold promise as potential treatments for Alzheimer's disease (AD) and related tauopathies. However, thus far epothilone D has been the only brain-penetrant MT-stabilizer to be evaluated in tau transgenic mice and in AD patients. Furthermore, this natural product exhibits potential deficiencies as a drug candidate, including an intravenous route of administration and the inhibition of the P-glycoprotein (Pgp) transporter. Thus, the identification of alternative CNS-active MT-stabilizing agents that lack these potential limitations is of interest. Toward this objective, we have evaluated representative compounds from known classes of non-naturally occurring MT-stabilizing small molecules. This led to the identification of selected triazolopyrimidines and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function. Pharmacodynamic studies confirmed that representative compounds from these series enhance MT-stabilization in the brains of wild-type mice. Thus, these classes of MT-stabilizers hold promise for the development of orally active, CNS-directed MT-stabilizing therapies.